HLS Therapeutics Inc.
74D.F
2.10 EUR
1 Tag: -3.67% (-0.08 EUR)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer 74D.F
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Aktuelle News
-
HLS Therapeutics (TSX:HLS) Stock Fair Value Rises After Analysts Turn More Positive
Vorschau anzeigen
Price targets on HLS Therapeutics have widened, with the most optimistic research pointing to C$8 while more cautious views sit near C$5. This spread reflects the recent shift in analyst commentary, where some see an inflection point for growth and cash generation, while others prefer to wait for more proof in upcoming quarters. As you read on, you will see what is driving these views and how to track the evolving story around HLS Therapeutics. Stay updated as the Fair Value for HLS...
-
When Will HLS Therapeutics Inc. (TSE:HLS) Become Profitable?
Vorschau anzeigen
HLS Therapeutics Inc. ( TSE:HLS ) is possibly approaching a major achievement in its business, so we would like to...
-
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Vorschau anzeigen
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks a